Abstract Library

#2259 Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma

Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,

Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,

#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors

Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Atsuko K

Authors: Kasajima A, Pavel M, Darb-Esfahani S, Stenzinger A, Sasano H,

Keywords: neuroendocrine tumor, proliferation index ,